Kairos Pharma Clinical Trial Data
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.